Aldeyra Therapeutics, Inc. (ALDX) Dividend History

Company News

• Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

  Bragar Eagel & Squire, P.C. is investigating potential claims against Organon, Aldeyra, Landstar, and ICU Medical due to issues related to financial results, regulatory matters, and accounting fraud.

  GlobeNewswire Inc.

  Featured Companies: ICUI LSTR OGN
• ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

  Aldeyra Therapeutics, a biotechnology company, is being investigated for potential securities law violations related to the failure of its Phase III dry eye disease drug trial. The company's stock price declined significantly after the FDA issued a Complete Response Letter citing concerns with the trial data.

  GlobeNewswire Inc.
• Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

  Bragar Eagel & Squire, P.C. is investigating potential securities law violations by TechTarget and Aldeyra Therapeutics. TechTarget disclosed errors in its financial statements and a potential goodwill impairment charge, while Aldeyra received a Complete Response Letter from the FDA for its dry eye disease treatment.

  GlobeNewswire Inc.

  Featured Companies: TTGT
• ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

  Aldeyra Therapeutics (ALDX) is being investigated for potential violations of federal securities laws after its Phase III dry eye disease trial failed to demonstrate the efficacy of its lead drug candidate, reproxalap, causing a 75% stock drop.

  GlobeNewswire Inc.

  Featured Companies: RH VTRS
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

  Aldeyra Therapeutics, Inc. received a Complete Response Letter from the FDA for its dry eye disease drug candidate, stating that the NDA failed to demonstrate efficacy in adequate and well-controlled studies. This led to a significant drop in the company's stock price.

  GlobeNewswire Inc.